News

SmartWatchBloodPressure-22752×1536 488 KB

Google researchers trained an AI model on wrist pulse waveforms (photoplethysmography) and motion signals from a Pixel Watch 3 to flag likely hypertension without any cuff calibration. In a prospective five-site US study, 196 adults without heart disease or blood pressure medication wore the watch for about a week and completed 24-hour ambulatory blood pressure monitoring, the clinical gold standard. The watch correctly flagged 66% of people with hypertension and correctly cleared 90% of those without it. A standard office reading caught 55% at the same specificity, but the difference was not statistically significant, and the overall accuracy of the two methods was nearly identical. Performance improved with wear time and leveled off at about an hour of usable data per day over five days. The system is meant as a screening prompt, not a diagnosis, and it was built and tested by the company that plans to sell it.

Roughly half of adults with high blood pressure have no idea they have it. The condition has no symptoms, and the standard way to find it, a cuff reading at a doctor’s office, is both infrequent and surprisingly unreliable. Office readings miss about half of people whose blood pressure is elevated across a full day, partly because some people relax in the clinic and spike everywhere else.

Google’s team took a different approach. Instead of trying to make a watch measure blood pressure directly, which has frustrated engineers for years, they asked a simpler question: does the shape of your pulse, recorded thousands of times over a week, carry a lasting signature of hypertension?

The watch’s green optical sensor records a pulse waveform with every heartbeat. Its accelerometer, during still moments, picks up the faint recoil of the body as the heart ejects blood into the aorta. The researchers first trained a neural network on nearly half a million hours of unlabeled watch data, teaching it to recognize what makes one person’s signals distinctive. They then trained a simple classifier to link those patterns to hypertension in 663 people who had worn a 24-hour blood pressure monitor.

The real test came in 196 new volunteers at five US sites, deliberately diverse in skin tone and age, and enriched for people with borderline readings. Each wore the watch for about a week, wore a 24-hour cuff monitor, took home readings, and had office readings taken. By the 24-hour standard, 39% had hypertension.

The watch caught 66% of them and wrongly flagged 10% of people without it. A single office visit caught 55% with the same false-alarm rate. Overall accuracy was essentially the same for both. The watch did better than a model using only age, sex and body mass index.

What the AI noticed fits known physiology. People it rated as high risk had pulse waves with a slower upstroke and altered reflected-wave timing, which are classic features of stiffer arteries. Their accelerometer traces showed a deeper dip corresponding to blood decelerating in the aorta.

The two methods also missed different people. About half the hypertensives missed in the office were caught by the watch. These are cases of so-called masked hypertension, which are especially easy to overlook.

There are important caveats. The study cohort had far more hypertension than the general population, which makes the device look more precise than it will be in everyday use. Almost all authors work for Google, which has already announced blood pressure features for its newer watches. The model has not been shown to track changes in blood pressure over time, so it cannot tell you whether a new diet or supplement is working. And because a third of the participants had already been flagged once, real-world sensitivity may be closer to the 50% seen during development.

Still, this is the first wrist-based hypertension screen validated against 24-hour monitoring rather than home cuffs. For people who never see a doctor, it could provide a nudge they would otherwise never get.

Actionable insights

The main message is that one normal office reading is weak reassurance. In this study, a single office visit missed 45% of people who were hypertensive over 24 hours. The watch missed 34%.

At matched false-alarm rates (10%), the watch caught about 8 more hypertensives per 76 than the office reading, a 10.5 percentage point gain. That gain was not statistically certain. Overall discrimination was similar: AUROC 0.856 for the watch versus 0.865 for office BP. Both correspond to a standardized separation of about 1.5, which is a large effect.

In a population where 20% have hypertension, a watch alert would raise your probability of having it from 20% to about 62%. No alert would lower it to about 9%. So an alert means “get a cuff,” and no alert does not mean “you’re fine.”

Practical steps:

• If you are flagged, or if you want to rule out hypertension, do 7 days of home readings (morning and evening, seated, two readings each time) or a 24-hour ambulatory study. Home monitoring over 3 or more days had 89% sensitivity in this study’s subgroup.
• Wear the watch at least an hour a day with good fit for 5 or more days; accuracy plateaued there.
• Do not use this feature to judge whether an intervention lowers your blood pressure. That has not been tested.

Context and source

• Paywalled Paper: Opportunistically Detecting Signs of Hypertension on a Consumer Smartwatch
• Institutions: Google Research (Cambridge MA, Mountain View CA, Seattle WA); University of Washington; Beth Israel Deaconess Medical Center/Harvard Medical School
• Country: United States
• Journal: Nature, published online 5 November 2026
• Funding: Alphabet Inc.; 14 of 16 authors are Alphabet employees; patent application filed
  Impact evaluation: The impact score of this journal is 56.1 (Clarivate JIF 2025), evaluated against a typical high-end range of 0 to 60+ for top general science journals, therefore this is an Elite impact journal.

NovosCoreVascularBenefits-22752×1536 460 KB

A six-month randomized, double-blind trial from the University of Surrey tested NOVOS Core, a daily 15 g powder combining twelve ingredients including glycine, calcium alpha-ketoglutarate, glucosamine, magnesium malate, fisetin, pterostilbene and low-dose lithium, in 61 healthy adults over 40. Among the 43 who finished, the supplement raised brachial flow-mediated dilation, a measure of how well arteries relax, by 2.9 percentage points more than placebo. It also reduced device-estimated pulse wave velocity by 1.18 m/s and lowered systolic blood pressure by 6.1 mmHg. Cholesterol and triglycerides did not change. Modeled 10-year cardiovascular risk fell by 0.45 percentage points, driven almost entirely by blood pressure. Effects appeared within one hour of the first dose. The trial was small, funded by the manufacturer, lost 30% of participants, and cannot say which ingredients matter.

Arteries age before people notice. Long before a heart attack or stroke, the inner lining of blood vessels loses its ability to release nitric oxide and relax, the aorta stiffens, and systolic blood pressure creeps upward. These three changes form the core of what cardiologists call vascular aging, and each predicts future cardiovascular events independently.

A team led by vascular physiologist Christian Heiss at the University of Surrey asked whether a supplement built on geroscience principles could push these markers in the right direction. The product, NOVOS Core, mixes twelve compounds that have each shown some anti-aging promise in worms, flies, mice or small human studies. The list reads like a longevity forum shopping cart: glycine, alpha-ketoglutarate, glucosamine, fisetin, pterostilbene, magnesium, vitamin C, L-theanine, Rhodiola, ginger, hyaluronic acid and a microdose of lithium.

Sixty-one healthy, non-smoking volunteers aged over 40 were randomly assigned to the powder or a taste-matched placebo for six months. The main measure was flow-mediated dilation, an ultrasound test that tracks how much the brachial artery widens after a cuff is released. Heiss’s lab is among the most experienced in the world at this test.

The results were significant. In people taking the supplement, artery dilation rose from about 5.5% to 8.1%, while the placebo group stayed flat. Systolic blood pressure dropped about 6 mmHg more than with placebo, roughly what a standard dose of a single blood pressure drug achieves. A device-based estimate of arterial stiffness also improved. Cholesterol did not budge.

Perhaps the most telling detail is timing. Artery function jumped within an hour of the very first dose, by an amount slightly larger than the six-month effect. That pattern suggests the product works mainly through a fast-acting effect on blood vessel tone that is renewed with each daily dose, rather than by slowly rebuilding aged arteries. The six-month measurements were taken about 24 hours after the last serving, so the study cannot tell lasting repair apart from lingering pharmacology.

There are good reasons for caution. Only 43 people completed the trial. The placebo group started out about five years older. The manufacturer funded the work, and one of its employees is a co-author. The effect on artery dilation is two to three times larger than what is typically seen with well-studied foods like cocoa flavanols or beetroot nitrate, and small trials with surprisingly large effects often shrink when repeated. The stiffness measure came from a cuff device that agrees poorly with the gold-standard method.

Still, the trial was properly randomized and blinded, the primary outcome was declared in advance, and the measurements came from a lab with a strong track record. If the blood pressure effect held up over years, large drug trials suggest it would cut heart attacks and strokes by around a tenth.

The next step is clear: a larger, independent trial with ambulatory blood pressure, gold-standard stiffness measurements and an attempt to identify which of the twelve ingredients is doing the work.

Actionable insights

For adults over 40 with normal to high-normal blood pressure, this trial suggests a specific daily blend may improve how arteries relax and modestly lower systolic pressure. The artery relaxation test improved by 2.9 points from a starting average of 5.5, about a 50% relative gain. In standardized terms that is a Cohen’s d of roughly 1.6, where anything above 0.8 counts as large. Treat that number with suspicion, since effects this big in small trials usually shrink on replication.

Systolic pressure fell about 6 mmHg more than placebo (d about 0.7, medium to large). Large drug-trial meta-analyses link each 5 mmHg drop to about 10% fewer heart attacks and strokes, so if sustained for years this could mean roughly 12% lower relative risk. In absolute terms, for a typical participant with 3% ten-year risk, that is about one event prevented per 220 to 280 people over a decade.

Practical steps: if you try this or any vascular supplement, take home blood pressure readings for two weeks before and after 8 to 12 weeks of use, since your own response is the most useful data you will get. Do not substitute it for prescribed medication. Expect no cholesterol benefit. Single ingredients with independent replication, such as magnesium, dietary nitrate and cocoa flavanols, remain reasonable lower-cost alternatives.

Context and source

• Open Access Paper: Acute and 6-month vascular effects of a multi-component nutritional supplement: a randomized controlled trial
• Institution: Faculty of Health and Medical Sciences, University of Surrey, Guildford, with Royal Surrey NHS Foundation Trust and Surrey and Sussex Healthcare NHS Trust; one co-author from NOVOS Labs, New York
• Country: United Kingdom
• Journal: European Heart Journal Open (European Society of Cardiology, Oxford University Press)
• Funding: NOVOS Labs supplied product and placebo and made an unrestricted research contribution
• Impact evaluation: The impact score of this journal is 4.3 (Clarivate JIF 2025), evaluated against a typical high-end range of 0 to 45+ for top cardiology journals (the flagship European Heart Journal sits near 45), therefore this is a Medium impact journal.

IGF1DownCogSpeedUp-22752×1536 500 KB

Researchers at Loyal Animal Health tested whether lowering insulin-like growth factor 1 (IGF-1) late in life changes how aged dogs think. Twenty-eight laboratory beagles aged 7 to 15, all experienced with cognitive testing, received a single injection of long-acting octreotide, a somatostatin analog that suppresses growth hormone, or saline. Octreotide cut circulating IGF-1 by about 29 percent at its peak, four weeks after dosing. Across three standard tests of attention, cognitive flexibility, and spatial working memory, treated dogs responded faster and were less likely to stall when task rules changed. They were not more accurate: correct answers, error counts, and memory scores were the same in both groups. The authors interpret this as improved processing efficiency and engagement.

Dogs, like people, slow down mentally as they age. Senior dogs take longer to choose, hesitate more when rules change, and are easier to distract. A new study from Loyal, a San Francisco company developing longevity drugs for dogs, asks whether a hormone that drives growth early in life might contribute to that slowdown later on.

The hormone is insulin-like growth factor 1, or IGF-1. Across worms, flies, and mice, animals with weaker growth hormone and IGF-1 signaling tend to live longer, and dwarf mice lacking growth hormone signaling keep their learning and memory skills deeper into old age. In dogs the pattern shows up across breeds: small breeds carry lower IGF-1 and live years longer than giant breeds. People with acromegaly, a condition of excess growth hormone, often have attention and memory problems.

To test the idea directly, the team took 28 laboratory beagles between 7 and 15 years old, all experienced at puzzle-box testing. Half received one intramuscular injection of long-acting octreotide, a drug used in people to treat acromegaly (high growth hormone levels). The other half got saline. Octreotide lowered blood IGF-1 by about 29 percent at its peak, four weeks after the shot, before levels began to rebound.

The dogs then worked through three classic tests. In one, they had to pick a familiar rewarded object while ignoring up to three decoys. In another, the reward rule was flipped so the object they had learned to ignore became the right one. In the third, they had to remember where a block had been after a delay of 20 or 90 seconds.

The treated dogs were quicker. With decoys present, they reached the correct object faster than placebo dogs. When the rules flipped, placebo dogs increasingly froze and made no choice at all, while treated dogs kept responding at their usual rate. In the memory task, treated dogs also responded faster, and the weakest performers appeared to gain the most.

What did not change matters just as much. Treated dogs were no more accurate in any test. They made the same number of errors, chose correctly at the same rate, and remembered locations no better. The authors themselves describe the result as better efficiency and engagement, not better memory.

That distinction leaves room for other explanations. A drug that alters gut hormones and digestion could change how hungry or alert a dog feels when food is the reward. The treated dogs were also already faster on the memory task before they received the drug, which weakens that result. With 14 dogs per group, one dose, and about six weeks of follow-up, the findings are early.

Still, the study offers something the field lacked: a randomized test of lowering IGF-1 in animals that are already old, rather than in mice engineered from birth. It suggests that dialing down this growth signal late in life does not blunt the aging brain in the short term, and may modestly speed it up. For Loyal, which is developing IGF-1-lowering drugs to extend the lives of large dogs, that is a useful early signal. Whether it translates into longer, sharper lives, in dogs or in people, is testing that is in process.

Actionable insights

The dog dose (about 0.9 mg per kg) converts on a body-surface basis to roughly 0.5 mg per kg in humans, around 34 mg for a 70 kg adult, which sits in the upper part of human acromegaly dosing.

How big was the benefit? In the distraction test, treated dogs got about 0.13 seconds faster than placebo dogs, roughly 13 percent of their starting response time. In standard terms that is a large effect (Cohen’s d about 0.9), but with only 14 dogs per group the true effect could plausibly be anywhere from trivial to very large. In the rule-switch test, placebo dogs stalled on about 7 more trials each, out of up to 200. On accuracy, the effect was zero.

The practical take-home is conceptual: modestly lower IGF-1 in late life did not harm cognition over six weeks, and may help. Keep in mind that very low IGF-1 is also linked to higher mortality in older adults, so the target is moderation, not suppression

Context and source

• Open Access Paper: Octreotide treatment improves multiple domains of cognitive performance in aged beagle dogs
• Institution: Loyal Animal Health, Inc., San Francisco, California. Animal work was approved by the InterVivo Solutions IACUC and followed Canadian Council on Animal Care guidelines, which indicates testing at a contract research facility in Canada [Confidence: Medium].
• Country: United States (sponsor), Canada (probable testing site)
• Journal: Frontiers in Veterinary Science (published 4 November 2026)
• Impact evaluation: The impact score of this journal is 3.1, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Low impact journal.

#### Related Reading:

• Fountain of Youth in the Veins: How Young Blood Restores Brain Blood Flow via IGF-1
• Loyal Raises $100 Million: Dog Longevity Drugs targeting IGF-1 and PPAR pathways
• Brain-Targeted IGF-1: The Perils of Over-Saturating the Longevity Switch
• How to reduce IGF-1 level instead of fasting
• Rare genetic variants in the IGF-1 / mTOR signalling pathway identified in exceptionally long-lived individuals
• Hi Testosterone, low IGF-1 phenotype
• IGF-1 inhibitors and lifespan extension?

FatFreeMassMetobolic-22752×1536 496 KB

Researchers at Pennington Biomedical Research Center analyzed 59,269 UK Biobank participants with both DXA and MRI body composition scans. They asked why higher fat-free mass, usually considered metabolically protective, keeps turning up in large studies as a risk factor for insulin resistance. Absolute fat-free mass and fat-free mass scaled to height were linked to more metabolic syndrome and elevated HbA1c. Fat-free mass as a share of body weight was strongly protective. Interaction models suggested visceral fat had the largest influence on these relationships, while fat infiltrating thigh muscle and sex hormones had smaller, inconsistent effects. The core finding, that the lean-mass paradox mostly reflects overall body size and fat, is plausible.

Ask most fitness coaches and doctors, and they will tell you that more muscle is good for your metabolism. Muscle is the body’s largest consumer of blood sugar, and building it is a standard prescription for preventing diabetes. Yet several large population studies have found the opposite pattern: people with more fat-free mass are more likely to be insulin resistant.

A team led by Candida Rebello at Pennington Biomedical Research Center in Louisiana set out to explain this paradox using one of the richest body composition datasets in the world. They drew on nearly 60,000 UK Biobank volunteers who had both a DXA scan, which estimates lean and fat mass, and an MRI scan, which can measure fat deep in the abdomen and fat marbled through the thigh muscles.

The paradox showed up clearly. People in the top third for total fat-free mass were about twice as likely to have metabolic syndrome as those in the bottom third. But when fat-free mass was expressed as a share of body weight, the picture reversed. Those with the leanest body composition had about one-fifth the rate of metabolic syndrome of those with the least.

The explanation is mostly arithmetic. Larger people carry more of everything: more muscle, more bone, more organ mass and more fat. Fat-free mass is not the same as muscle; only about half of it is skeletal muscle. A high absolute lean mass often simply marks a big body that also carries a lot of fat.

The researchers then tested whether visceral fat, fat infiltrating muscle, or sex hormones changed these relationships. Visceral fat had the clearest influence. Fat infiltrating muscle had effects that were statistically significant but tiny, and sometimes pointed in opposite directions depending on how lean mass was measured. Sex hormones had modest effects that mostly disappeared when men and women were analyzed separately.

The study has notable weaknesses:

• In UK Biobank, blood tests were taken at enrollment in 2006 to 2010, while body scans began in 2014. The paper does not say which visit its blood data came from. The average age it reports matches the earlier visit, suggesting body composition was measured years after the metabolic outcomes.
• The authors claim their estimates are precise enough to show real differences across levels of muscle fat. For muscle fat, the confidence intervals overlap.
• Even MRI-measured thigh muscle volume, the purest muscle measure in the study, showed the same paradoxical pattern. That points to body size rather than poor muscle quality.

For readers, the practical lesson is sound even if the study cannot fully prove it. The absolute amount of lean mass on a body composition scan says little about metabolic health on its own. What matters more is how much fat surrounds it, especially in the abdomen.

Actionable Insights

• Read your DXA scan for ratios, not totals. In this cohort, people in the top third for lean-mass share of body weight had metabolic syndrome at 7.5 percent, versus 35.9 percent in the bottom third, roughly 79 percent lower. Each 4-percentage-point higher lean share (equivalent to 4 points lower body fat) went with about 55 percent lower odds. [Confidence: Medium, observational]
• Prioritize visceral fat. Metabolic syndrome rose from 6 percent in the lowest third of visceral fat to 36.6 percent in the highest, about six-fold. Elevated HbA1c rose from 6.6 to 17.2 percent. Many DXA reports estimate visceral fat directly; track it. [Confidence: High for direction]
• Train for quality, not just quantity:
  • Resistance training builds muscle.
  • Aerobic training and weight loss reduce visceral fat and fat within muscle.
  • The combination addresses both.
• Do not assume adding lean mass alone protects you. A 3 kg gain in absolute lean mass corresponded to about 45 percent higher odds of metabolic syndrome in this cohort. That almost certainly reflects larger bodies carrying more fat, not harm from muscle, but it means lean mass gained alongside fat gain buys little.

Context and Source

• Open Acccess Paper: Relationship between fat-free mass and metabolic syndrome is shaped by ectopic fat in a UK Biobank cohort, Published 08 October 2026.
• Institution: Pennington Biomedical Research Center, Louisiana State University System
• Country: USA (UK Biobank data)
• Journal: The Journal of Clinical Endocrinology & Metabolism (Endocrine Society / Oxford University Press).
• Impact evaluation: The impact score of this journal is 5.1, evaluated against a typical high-end range of 0-45 for endocrinology and metabolism journals (Lancet Diabetes & Endocrinology and Nature Reviews Endocrinology near the top), therefore this is a Medium impact journal. It is the flagship clinical journal of the Endocrine Society.

vo2maxBiockockrate-22752×1536 487 KB

Japanese researchers measured peak oxygen uptake with breath-by-breath gas analysis in 144 men aged 65 to 72 and compared it with DunedinPACE, a blood DNA methylation measure of how fast a person is biologically aging. Men with higher aerobic fitness tended to have a slightly slower pace of aging, and the link held after accounting for age, smoking, and drinking. Using a resampling-based classification analysis, the team proposed 26.2 mL/kg/min as a fitness threshold separating slower from faster agers. Dietary copper and iron intake and HDL cholesterol also tracked with slower aging, while muscle strength did not. The associations were weak, explaining about 3 percent of the variation in aging pace, and the single-timepoint design cannot show that fitness causes slower aging.

Aerobic fitness has one of the strongest track records in longevity research. People who can take up more oxygen during hard exercise live longer and have fewer heart attacks, a pattern that has held across decades of follow-up studies. What has been less clear is whether that fitness shows up in the molecular signals used to track biological aging.

A team led by Takuji Kawamura at Tohoku University and Waseda University tested this in 144 Japanese men aged 65 to 72, all alumni enrolled in a long-running health study. Each man completed a graded cycling test while breathing through a mask that captured every breath, giving a direct measure of peak oxygen uptake, the gold standard for cardiorespiratory fitness. The researchers then analyzed DNA methylation in blood using DunedinPACE, which estimates how many years of biological aging a person accumulates per calendar year. A score of 1.00 means aging at the expected rate; 0.90 would mean about 10 percent slower.

The fitter men did tend to age more slowly by this measure, and the relationship survived adjustment for age, smoking, and drinking. Muscle strength, by contrast, showed no link at all. That points to the heart, lungs, and oxygen-burning capacity of muscle, rather than raw force, as what tracks with the methylation signal.

The team then asked whether a specific fitness level separates slower agers from faster ones. Resampling the data 2,000 times, they settled on 26.2 milliliters of oxygen per kilogram of body weight per minute. That sits above the typical value of about 22.7 for men this age on a cycle test, which the authors read as a sign that above-average fitness is what counts.

Diet appeared in the results too. Men who reported eating more copper and iron per calorie, and men with higher HDL cholesterol, had slower aging scores. Men carrying more visceral belly fat aged slightly faster.

The size of the effect needs to stay in view. Fitness explained roughly 3 percent of the differences in aging pace. In practical terms, a man about one standard step fitter than his peers (4.6 units of oxygen uptake) would be expected to accumulate five or six fewer days of biological aging per year. The cutoff sorted men only modestly better than chance, and the authors concede it has limited value for judging any one person.

There is also a chicken-and-egg problem. Each man was measured once, so the study cannot tell whether fitness slows aging or whether men aging slowly for other reasons find it easier to stay fit. DunedinPACE was also originally built partly from declines in aerobic fitness, so some overlap is baked into the measure.

Still, the work links a trainable trait to a blood-based aging rate in older adults and gives researchers a concrete number to test. The obvious next step is a trial: train older adults past the 26.2 line and see whether their DunedinPACE scores actually fall.

Actionable Insights

• Get a real measurement. A cardiopulmonary exercise test gives true VO2peak. The study’s 26.2 mL/kg/min line was set on a stationary bike; treadmill tests usually read about 10 to 15 percent higher, so the treadmill equivalent is likely near 29 to 30. [Confidence: Medium]
• Train the engine. Structured endurance or interval training typically raises VO2peak in older adults by roughly 10 to 20 percent over three to six months, enough to move a man from 23 to the mid 20s.
• Remember the denominator. The target is per kilogram. An 80 kg man who loses 5 kg of fat while keeping the same absolute oxygen uptake raises his score by about 7 percent.
• Keep expectations realistic. Each 4.6-unit fitness advantage lined up with about 1.5 percent slower DunedinPACE, or 5 to 6 fewer days of biological aging per year. Being above the cutoff raised the estimated chance of being a slow ager from about 46 percent to about 56 percent. The stronger reason to train comes from outcome studies: each extra 1 MET (3.5 units) of fitness is linked to about 13 percent lower all-cause mortality.
• If you take metformin, note that one trial in older adults found it blunted mitochondrial and insulin-sensitivity gains from aerobic training. [Confidence: Medium]
• Copper and iron here were diet estimates, not blood levels. This is not a case for supplements.

Context and Source

• Open Access Paper: Revisiting the relationship between cardiorespiratory fitness and biological aging: insights from DunedinPACE analysis, published 30 October 2025
• Institutions: Smart Aging Research Center, Tohoku University (corresponding author); Faculty of Sport Sciences, Waseda University; with co-authors at Juntendo University, Sophia University, Meiji Yasuda Life Foundation, and the Hungarian University of Sports Science
• Country: Japan (one co-author in Hungary)
• Journal: GeroScience (2026)
• Impact evaluation: The impact score of this journal is 4.9, evaluated against a typical high-end range of 0-20 for aging and geroscience journals (Nature Aging sits near the top of that range), therefore this is a Medium impact journal.

VibrationsAndNitricOxide-22752×1536 488 KB

Finnish researchers tested whether manipulating blood vessels could push proteins out of the human brain and into the bloodstream. Twenty-nine healthy adults aged 27 to 61 received sublingual nitroglycerin, a nitric oxide donor that relaxes arteries and lowers blood pressure, combined with 37 minutes of patterned whole-body vibration designed to stimulate the mechanosensitive Piezo1 channel. After the combined session, blood levels of amyloid-beta 40, amyloid-beta 42 and the astrocyte protein GFAP rose by roughly 30 to 35 percent, and the size of the rise tracked how far blood pressure fell. MRI showed brain tissue signal darkening, more fluid around the brain and brighter signal in posterior venous sinuses. Larger proteins, neurofilament light and phosphorylated tau, did not change. The findings hint at a non-invasive way to boost brain clearance, but the study was small and short, and its key blood measurements had no control arm.

Every night while you sleep, your brain rinses itself. Cerebrospinal fluid washes through brain tissue and carries away waste proteins, including the amyloid-beta that clumps into plaques in Alzheimer’s disease. This plumbing, often called the glymphatic system, appears to falter with age, and many researchers suspect the failure begins years before memory does. A team led by Vesa Kiviniemi at the University of Oulu in Finland asked a direct question: can we turn that drainage up in awake humans?

Their approach targeted the blood vessels that drive brain fluid flow. Nitric oxide relaxes arteries, and in mice, lowering blood pressure with nitric oxide donors pushes cerebrospinal fluid tracers out of the skull and into the blood. A second lever is Piezo1, a channel in vessel walls that responds to mechanical force. Gentle mechanical stimulation of Piezo1 in mice restores sluggish lymphatic drainage in the neck. The Finnish group combined both. Volunteers placed a nitroglycerin tablet under the tongue, the same drug used for angina, then lay on a vibrating mattress that cycled between 22 and 50 hertz in a pattern meant to keep Piezo1 responsive rather than numb.

The results were clear in direction, if modest in scale. Blood pressure fell by about 15 percent at its lowest point. Blood levels of two forms of amyloid-beta and of GFAP, a protein made by the brain’s astrocyte support cells, rose by roughly a third after correcting for the blood thinning that nitroglycerin causes. People whose blood pressure dropped the most showed the biggest protein rises. Two larger brain proteins, neurofilament light and phosphorylated tau, did not budge, which the authors read as a size filter on the exit route.

Brain scans told a parallel story. A clinical MRI sequence sensitive to the protein content of water showed the whole brain darkening slightly, the fluid space around the brain expanding by about 6.5 milliliters, and signal brightening in two large veins at the back of the head. Blood amyloid levels correlated, weakly, with that venous signal. Changes were larger in older participants. Nitroglycerin alone reproduced much of the brain darkening, vibration alone did little the scanner could detect, and the combination affected a wider area of brain than either alone.

The authors draw a parallel to sleep. Nitroglycerin amplified slow oscillations in blood vessel diameter near 0.1 hertz and breathing-linked pulsations, rhythms that intensify in deep sleep and are thought to pump fluid through the brain.

The study has important gaps. It enrolled 29 healthy adults and measured blood proteins once, about 90 minutes after treatment. It did not measure blood proteins at all after vibration alone, nitroglycerin alone or a sham session. A rise in blood amyloid could mean more protein leaving the brain, but it could also mean slower removal of amyloid by the liver and kidneys while blood pressure is low, or a temporary loosening of the blood-brain barrier. Nobody yet knows whether repeated treatment would lower brain amyloid or protect memory.

What the paper does establish is that human brain fluid dynamics respond measurably, within a couple of hours, to deliberate vascular manipulation. That moves the brain’s drainage system closer to being a practical therapeutic target rather than a purely theoretical one.

Insights

1. In this trial, one volunteer taking nitroglycerin vomited and withdrew, and others had headaches or nausea. Combining nitrates with PDE5 inhibitors such as tadalafil or sildenafil can cause dangerous, potentially fatal drops in blood pressure. For repeated or long-term use for this purpose: Safety Data Absent.
2. The benefit measured is a short-term biomarker shift, not a health outcome. Blood amyloid rose about a third, a moderate effect (Cohen’s d about 0.5, meaning the average person moved about half of the normal person-to-person spread). The size of the blood pressure drop explained roughly 25 to 40 percent of the variation in that rise. Memory, plaque load and dementia risk were not measured.
3. Deep sleep naturally produces similar vascular pulsations. Long-term blood pressure control has real outcome data: in the SPRINT MIND trial, intensive control lowered the risk of mild cognitive impairment by about 19 percent (hazard ratio 0.81).
4. Vibration platforms are low risk, but here vibration alone produced only small imaging changes and was never tested on blood biomarkers.
5. Endothelial nitric oxide production declines with age. Regular aerobic exercise is the best-documented way to maintain it.

Context and Source

• Open access Paper: Vasomechanic treatment is associated with increased efflux of human brain proteins
• Institution: Oulu Functional Neuroimaging, University of Oulu and Oulu University Hospital, with collaborators at Lund University, University of Eastern Finland and Kuopio University Hospital, University of Rochester, and University of Copenhagen (Maiken Nedergaard’s group)
• Country: Finland (lead), with Sweden, USA and Denmark
• Journal: Nature Communications
• Impact evaluation: The impact score of this journal is 18.1, evaluated against a typical high-end range of 0-60+ for top general science, therefore this is a High impact journal.

Related Reading:

• Vibrating mattress helps clear Alzheimer’s protein from the brain (New Scientist)
• My Dementia Avoidance Protocol - Please improve it and offer advice
• Predicting and Preventing Alzheimers & Dementia (and minimizing risk)
• How the Collapse of Nitric Oxide Signaling Accelerates Aging
• Broken Vessels: How Sugar, Insulin, and a Rogue Glycoprotein Starve the Heart of Protective Nitric Oxide

RecoveryAsAgingMeasure-22752×1536 426 KB

Researchers from Swedish Medical Center and the University of Denver argue that aging is best understood as a progressive loss of “biological self-correction”: the body’s ability to sense a disturbance, mount a proportionate response, repair damage, switch the response off and recover while keeping reserve for the next challenge. Rather than replacing the hallmarks of aging, the framework treats them as candidate mechanisms behind impaired recovery. The authors propose measuring aging dynamically, by tracking how people respond to and recover from standardized stressors such as exercise, vaccination or a glucose challenge, instead of relying only on resting biomarkers like epigenetic clocks. They rank longevity interventions by evidence, placing exercise and cardiometabolic control at the top and NAD+ precursors, senolytics and partial reprogramming well below.

A thermostat is judged not by the temperature in a quiet room but by how well it handles an open window. A new review argues that human aging should be judged the same way.

David Bar-Or and colleagues, writing in the journal Geriatrics, propose that aging is fundamentally a decline in “biological self-correction.” Young bodies take constant damage too, they note, but they detect it quickly, respond in proportion, repair it and then switch the response off. With age, each step can falter. Responses come late or overshoot. Repairs are incomplete. Inflammation that should end keeps smoldering. And sometimes the body settles efficiently into a worse equilibrium, such as chronically raised inflammation or blood pressure, and then defends that state as if it were normal.

This view does not discard the familiar hallmarks of aging, such as DNA damage, failing protein quality control, dysfunctional mitochondria and senescent cells. Instead it treats them as possible reasons the correction cycle breaks down. Senescence, for example, starts as a sensible defense against cancer but becomes harmful when the immune system stops clearing the arrested cells.

The practical proposal is a shift in measurement. Rather than reading biological age from a single blood draw, researchers would apply a defined stress, such as an exercise test, a vaccine or a sugary drink, and track the response over time: how far function drops, how quickly it returns, what it costs and whether reserve remains for the next challenge. The authors list ten or more trajectory features to capture.

The review is also notably sober about popular longevity strategies. NAD+ precursors reliably raise NAD+ levels in blood but have not consistently improved function in human trials. Senolytics remain preliminary in people. Partial reprogramming is still a laboratory tool with cancer risks. Even mTOR inhibition is framed carefully: the authors suggest healthy aging may depend on switching flexibly between growth and maintenance modes rather than keeping growth signaling permanently low (a position that is well known in the Longevity / rapamycin user community already).

At the top of their evidence ranking sit unglamorous interventions: physical activity, resistance training, not smoking, blood pressure and metabolic control, vaccination, sleep and diet. Exercise gets special emphasis because it is both a controlled stress and a way of training the body’s response to stress.

The weaknesses are real. The paper presents no new data, and its literature search was not systematic. The authors acknowledge that “self-correction” overlaps heavily with existing ideas such as resilience, allostasis and physiological reserve. More importantly, the review omits a body of work that has already measured recovery dynamics in humans, including analyses of blood markers showing that recovery from fluctuations slows with age. With so many possible stressors, readouts and trajectory measures, and an escape clause for “defended” unhealthy setpoints, the framework may be harder to falsify than the authors suggest.

Still, the core idea has value. A clock that reads lower after a supplement means little if you recover no better from illness, surgery or a hard week. Measuring how people bounce back, not just how they look at rest, is a reasonable next step for the field.

Actionable insights

The review generates no new data, so its practical messages rest on the human studies it cites.

1. Resistance training. In a meta-analysis of cohort studies, any resistance training versus none was linked to 15 percent lower all-cause mortality (Cohen’s d approx. 0.09, small), with the largest reduction, about 26 percent, at roughly 60 minutes per week and no extra benefit beyond. Combining resistance and aerobic activity was linked to 40 percent lower mortality versus doing neither (d approx. 0.28). For a group with 10 percent ten-year mortality, that is about 4 fewer deaths per 100 people. These are observational associations.
2. Lifestyle base. Adults with five low-risk habits (never smoking, regular activity, healthy weight, good diet, moderate alcohol) had projected life expectancy at age 50 that was 14.0 years longer for women and 12.2 years for men than those with none.
3. Experimental agents. NAD+ precursors show target engagement without consistent functional benefit; senolytics remain preliminary in humans. Avoid indiscriminate stacking.
4. Self-tracking. Recovery metrics such as heart rate variability rebound after training or glucose return-to-baseline after meals fit this framework, but none are validated as aging measures.

Context and source

• Open Access Paper: Aging as Loss of Biological Self-Correction: A Geroscience Framework for Longevity, Inflammaging, and Restored Resilience
• Institutions: Trauma Research Department, Swedish Medical Center, Englewood, Colorado; Knoebel Institute for Healthy Aging, University of Denver
• Country: USA
• Journal: Geriatrics (MDPI), published 16 September 2026.
• Impact evaluation: CiteScore 3.4, Q2 in Gerontology. The impact score of this journal is 2.4, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Low impact journal.

Related Reading:

• One Man, Seven Months, One Data Point: Can Your Biology's Recovery Speed Become the New Biomarker?
• Loss of Resilience as the Key Measure of Aging, And How to Track It
• Heart Rate Recovery Time: The simple fitness test that predicts your risk of death (BBC)
• The Heart That Beats Too Evenly: Heart Rate Variability Tracks the Aging Brain
• Pregnancy Ages the Body. The Time Between Babies May Decide Whether It Sticks
• Too Hot to Sleep: Nighttime Temperatures Above 24°C Impair Autonomic Recovery in Older Adults

RiboflavinButyrate-22752×1536 490 KB

The RIBOGUT trial randomized 105 healthy Dutch adults to placebo, 50 mg/day, or 100 mg/day of oral riboflavin for two weeks, testing whether high-dose vitamin B2 could expand populations of Faecalibacterium prausnitzii, a butyrate-producing gut anaerobe repeatedly linked to gut health. The primary endpoint failed outright. F. prausnitzii abundance did not change by either fluorescence microscopy or 16S sequencing, and neither did overall microbial diversity or community composition. Secondary findings were more interesting. Fecal butyrate concentration rose in the 100 mg group, and rose more convincingly when both riboflavin arms were pooled in a post hoc analysis. Network analysis suggested the bacterial community became more interconnected. A small substudy showed non-significant upward trends in post-glucose insulin and GLP-1 at the higher dose.

The Groningen team had a specific and reasonable hypothesis. Faecalibacterium prausnitzii is one of the most abundant bacteria in the human colon and one of the most consistently depleted in inflammatory bowel disease and obesity. It makes butyrate, the short-chain fatty acid that colon cells burn for fuel and that calms local inflammation. Earlier work had shown that F. prausnitzii uses riboflavin as an electron shuttle, letting it survive in the oxygen gradient near the gut wall where it otherwise would not. Give people enough riboflavin that some escapes absorption in the small intestine and reaches the colon, the logic went, and the bacterium should flourish.

It did not. Across 105 healthy volunteers taking 50 or 100 mg daily for a fortnight, F. prausnitzii numbers held completely flat. Two independent measurement methods agreed. Overall community diversity did not budge either. Where you landed in the microbial map at the start of the trial is where you were at the end.

The riboflavin definitely arrived. Fecal and plasma riboflavin levels climbed steeply in both supplemented groups and not at all in placebo, with some of the most decisive p-values in the paper. So this was not a delivery failure. The vitamin got there and the population census refused to move.

What moved was output. Fecal butyrate rose in the 100 mg group. When the investigators combined both riboflavin arms into a single larger group, a decision made after seeing the data, the butyrate increase became clearer. Acetate rose in the 50 mg group. The bacterial interaction network, a statistical map of which organisms rise and fall together, gained connections and tightened up in the supplemented participants while the placebo network thinned out over the same period.

The interpretation the authors offer is that the same microbial community simply started working differently. More cross-feeding, more metabolic traffic, more butyrate out the far end, with the roster unchanged. Riboflavin is a precursor to FAD and FMN, cofactors that sit at the heart of bacterial electron transport, so a plausible mechanism exists for why handing a community more redox currency would raise its metabolic throughput without changing who belongs to it.

Two cautions matter. The pooling of the dose groups was decided after the fact, which is the kind of analytic choice that generates positive findings from null trials. And the study was funded by DSM Nutritional Products, which employs one author and has since brought a colon-targeted riboflavin ingredient to market built on precisely this concept.

Still, the idea that an inexpensive vitamin might shift gut metabolic function without disturbing gut ecology is worth testing properly. This study is a signal, not a verdict.

Actionable Insights

First, the headline claim is weak but not empty. Pooling both dose groups, fecal butyrate increased from a median of roughly 10 to 11 mM before supplementation to roughly 15 mM after. That is a relative increase in the neighborhood of 35 to 45 percent. Translated into a standardized effect size, the paired comparison corresponds to roughly r = 0.30 to 0.34, which converts to a Cohen’s d somewhere near 0.6 to 0.7. In plain terms, a d of 0.6 means that if you lined up people before and after, the typical person after supplementation sits above about 73 percent of their own pre-supplementation distribution. That is a real but moderate shift, not a transformation.

Second, that number is almost certainly optimistic. It comes from a within-person before-and-after comparison inside a group created after the data were seen. The honest placebo-controlled between-group test of butyrate change was never reported. In the placebo arm, butyrate actually drifted downward over the same window, which means some of the apparent gain is regression to the mean and seasonal or dietary noise rather than drug effect.

Third, be aware. 50 to 100 mg/day is roughly 40 to 90 times the adult RDA. It was safe, and generally is at higher doses like this, but there are not a lot of studies. It will turn your urine bright yellow.

Fourth, if your goal is butyrate, fermentable fiber and resistant starch have substantially stronger and better-replicated human evidence than this. Combining both approaches could be a reasonable strategy.

Context and Source

• Open Access Paper: Riboflavin Supplementation Promotes Butyrate Production in the Absence of Gross Compositional Changes in the Gut Microbiota
• Lead institution: Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, The Netherlands.
• Journal: Antioxidants & Redox Signaling
• Country: The Netherlands. Co-affiliations in Australia (University of Adelaide) and Switzerland (DSM Nutritional Products AG, Kaiseraugst, and University Hospital Zurich).
• Impact Evaluation: The impact score of this journal is 6.1, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

Related Reading:

• Butyrate: The Microbiome's Anti-Aging "Kill Switch" for Senescent Cells
• Curcumin, Butyrate, and the Aging Immune System: A Microbiome-Centric Strategy for Longevity
• Butyrate extends health and lifespan in mice with mitochondrial deficiency (paper March 26)
• No Ceiling in Sight: More Fiber Tracks With Less Heart Disease Up to 35 Grams a Day
• Daily Oat Fiber Shows Potential to Trap Ingested Forever Chemicals Before They Enter the Blood

PurpleFoodforBrainREview-22752×1536 499 KB

This review from the University of California, Davis, gathers preclinical, clinical and cell-culture evidence on whether anthocyanins, the red, purple and blue pigments in berries, purple vegetables and pigmented grains, can protect the brain from the damage linked to obesity and high-fat Western diets. The authors argue that the benefits begin in the gut. Very little intact anthocyanin is absorbed, so the compounds act mainly by tightening the intestinal barrier, reducing leakage of bacterial endotoxin into the blood, reshaping the microbiome, and generating phenolic acid metabolites that circulate widely. Further downstream, rodent studies show reduced hippocampal inflammation, preserved BDNF, healthier glucocorticoid signaling and better performance on memory tests. Human data are thinner. Single-meal trials show smaller post-meal spikes in blood fat, glucose and endotoxin, but direct evidence that anthocyanins protect cognition in people with obesity remains inconclusive.

Your brain may care what color your dinner is. That is the idea behind a new review from nutrition scientists at the University of California, Davis, who have pulled together more than a decade of research on anthocyanins, the pigments that make blueberries blue, blackcurrants inky and purple sweet potatoes purple. Their question is narrow but important: can these compounds blunt the harm that obesity and a fat-heavy Western diet inflict on the brain?

The harm itself is well documented. Obesity raises the risk of cognitive decline and dementia, and in rodents a high-fat diet reliably inflames the hippocampus, the brain’s memory hub. One leading explanation starts in the gut. Fatty diets loosen the seals between intestinal cells and change the microbial population, allowing fragments of bacterial cell wall called lipopolysaccharide, or LPS, to slip into the bloodstream. Even a single greasy meal can do this, because LPS hitches a ride on the fat particles absorbed after eating. Circulating LPS stirs up inflammation that can weaken the blood brain barrier and activate the brain’s immune cells.

The twist is absorption. Anthocyanins are poorly absorbed, and usually well under 5 percent of what you eat turns up in urine. For years that looked like a fatal flaw. The UC Davis team argues it is the point. Because most of the pigment stays in the gut, that is where it reaches concentrations high enough to matter. In mouse studies, anthocyanin extracts kept the intestinal barrier intact, reduced LPS leakage, shifted the microbiome toward species such as Akkermansia, and lowered inflammatory markers in the hippocampus. Gut microbes also break anthocyanins down into small phenolic acids, such as vanillic acid, which circulate at far higher levels than the parent compounds and appear to carry some of the benefit.

The review traces several downstream effects. Treated animals kept higher levels of BDNF, a protein that supports learning and neuron survival. Their stress hormone signaling looked healthier. Blood vessels produced more nitric oxide, which may improve blood flow to the brain. In fat tissue, anthocyanins switched on mitochondria-building programs and nudged white fat toward the more metabolically active “beige” type.

In people, the most striking data come from meal challenge studies. When 25 healthy young adults ate a roughly 1,000-calorie high-fat meal with a drink containing about 320 mg of anthocyanins, their post-meal rise in blood fats, glucose and LPS was smaller than with placebo, and BDNF released from blood cells increased. Separately, older adults who ate wild blueberry powder daily for 12 weeks showed better blood vessel function, lower systolic blood pressure and modest gains on some memory tasks.

There are gaps in the research review. Most of the brain evidence comes from short-term studies in young male rodents. Many studies used whole-food extracts loaded with other polyphenols, so the anthocyanins cannot be singled out. And whether anthocyanins protect cognition specifically in people with obesity is, by the authors’ own account, unresolved.

Still, the practical message carries little risk. Eating more deeply colored fruits and vegetables, especially alongside rich meals, is a cheap experiment with a plausible mechanism behind it.

Actionable Insights

Pair rich meals with dark berries. In a crossover trial, about 320 mg of anthocyanins taken with a high-fat meal lowered average blood triglycerides over five hours by roughly 21 percent (about 42 mg/dL lower than placebo).

Aim for about 300 mg of anthocyanins daily, roughly 178 g of fresh wild blueberries (a heaping cup). In older adults this improved artery dilation (FMD) by 0.86 percentage points and lowered 24-hour systolic blood pressure by about 3.6 mmHg over 12 weeks. Pooled data suggest that size of blood pressure drop corresponds to a population-level cardiovascular risk reduction in the single digits of percent.

If you are insulin resistant, blueberry bioactives (about two cups of berries daily) improved insulin sensitivity by 22 percent versus 5 percent on placebo over six weeks. About one extra person in every four treated reached a meaningful improvement.

Expect small lipid changes, not drug-like ones: LDL drops of around 7 mg/dL in pooled trials.

Do not expect a noticeable memory boost. Meta-analyses conflict. If the effect is real, it is small: the average person eating anthocyanins would score better than about 58 to 68 percent of non-eaters on cognitive tests.

Context and Source

• Paywalled Paper: Anthocyanins and brain health in the context of obesity and Western-style diets, published online 22 October 2026.
• Institution: Department of Nutrition and Department of Environmental Toxicology, University of California, Davis
• Country: United States
• Journal: Archives of Biochemistry and Biophysics
• Impact evaluation: The impact score of this journal is 3.6 (2025 JIF), evaluated against a typical high-end range of 0 to 50+ for top biochemistry and molecular biology journals, therefore this is a Medium impact journal.

Related Reading:

• The "Black Gold" of Grains: Black Rice Intake Sharpens Memory and Dampens Inflammation in Seniors
• Anthocyanins and Cardiometabolic Health: A Longevity Research Analyst Report
• Purified anthocyanins may reduce inflammatory biomarkers

TestosteronePhysicalCognitive-22752×1536 482 KB

This systematic review from Ariel University and collaborating Israeli centers asked whether naturally occurring androgen levels track physical and cognitive performance in healthy middle-aged men. Following PRISMA guidelines with prospective PROSPERO registration, the authors searched three databases for observational studies published between 2010 and 2026, screened 485 records and included 16: seven on physical function and nine on cognition. Free and bioavailable testosterone showed small positive associations with grip strength more consistently than total testosterone, and one longitudinal analysis found higher baseline free testosterone predicted lower risk of mobility limitation over 6.6 years. Cognitive findings were inconsistent across domains, with visuospatial ability showing the most reliable association. Effect sizes were uniformly small, standardized coefficients typically between 0.02 and 0.13.

Testosterone falls by roughly one to three percent per year from a man’s fourth decade onward. Around forty percent of middle-aged men eventually meet a laboratory definition of low testosterone. What that means for how they function has never been clear, because symptoms correlate poorly with the number on the lab report.

A team led by Dan Keren at Ariel University narrowed the question. Rather than asking whether giving men testosterone helps, which has been studied extensively in older and sick populations, they asked whether a man’s own hormone levels in midlife predict how well his body and mind work. They restricted the search to healthy men and to objective measurements: grip strength, walking speed, chair rises, memory tests, processing speed.

Sixteen studies qualified. Seven examined physical performance, nine examined cognition.

The physical side produced the more coherent picture. Across six studies measuring grip strength, free and bioavailable testosterone were associated with stronger grip more consistently than total testosterone. The distinction matters mechanically: most testosterone circulates bound to a carrier protein and is unavailable to tissue, so the free fraction should track biological effect better.

The single longitudinal result is the most useful finding in the review. In the Framingham Offspring cohort, men with higher free testosterone at baseline had a lower risk of developing mobility limitation over the following 6.6 years, with roughly a quarter lower odds. Total testosterone predicted nothing.

The cognitive side was messier. Nine studies, almost no agreement. Visuospatial ability showed the most consistent link to testosterone. Verbal and episodic memory produced contradictory results: one study found higher urinary testosterone predicted better word recall, another found free testosterone predicted worse recall, and a third found the direction depended entirely on a man’s cortisol level.

The size of all of this is the part that gets lost. Standardized coefficients for grip strength clustered between 0.09 and 0.13, meaning testosterone accounted for roughly one to two percent of the differences between men. One walking speed association had a coefficient of 0.02, which is indistinguishable from nothing. The grip strength difference between men with low and normal free testosterone was 2 kilograms, with a confidence interval reaching down to 0.07 kilograms. Typical male grip strength is 40 to 50 kilograms, and the smallest difference people can perceive is usually put at 5 to 6 kilograms.

The authors also report, in their discussion rather than their abstract, the finding that should anchor interpretation. Large randomized trials of testosterone treatment in men with hypogonadism have produced gains in muscle mass and strength but modest and inconsistent effects on actual physical performance, and no cognitive benefit at all.

That gap between observation and intervention is the familiar shape of a confounded association. Men who are more active, leaner and healthier have higher testosterone and also walk faster and grip harder. Fourteen of the sixteen studies measured everything at a single moment, which cannot separate those possibilities.

Actionable Insights

1. The measurable associations are too small to act on individually. Standardized coefficients for testosterone and grip strength ran from 0.09 to 0.13, accounting for roughly 0.8% to 1.7% of between-person variation. For context, a coefficient of 0.2 is conventionally the floor for a meaningful effect.
2. The one concrete clinical number is below the threshold people can feel. Men with low free testosterone had grip strength 2.0 kg weaker (95% confidence interval -3.95 to -0.07 kg). The minimal clinically important difference for grip strength is usually cited at 5 to 6 kg, and the upper bound of this interval is essentially zero.
3. If you are tracking hormones, free or bioavailable testosterone carried the associations more consistently than total testosterone. Note that free testosterone was calculated from total testosterone and binding globulin in nearly every study rather than measured directly, so part of its apparent advantage may be statistical rather than biological.
4. The longitudinal signal is the most credible: higher baseline free testosterone predicted about 22% lower odds of incident mobility limitation and 25% lower odds of progressive limitation over 6.6 years (odds ratios 0.78 and 0.75). This is one analysis in one cohort of older men.
5. Treatment does not reproduce the observation. The review cites 2025 evidence that testosterone therapy in hypogonadal men increases muscle mass and strength but has modest, inconsistent effects on physical performance and no cognitive benefit.

Context and Source

• Paywalled Paper: Endogenous androgens, physical and cognitive function in healthy midlife men: A systematic review
• Institutions: Faculty of Health Sciences, Department of Physical Therapy, Neuromuscular and Human Performance Laboratory, Ariel University; Division of Maternal Fetal Medicine, Helen Schneider Women’s Hospital, Rabin Medical Center, Petah Tikva; Sheba Longevity Center, Sheba Medical Center, Ramat Gan; Gray Faculty of Medical and Health Sciences, Tel Aviv University; Department of Management, Health Management Program, Bar-Ilan University
• Country: Israel
• Journal: Mechanisms of Ageing and Development, volume 234 (2026), article 112257
• Impact evaluation: The impact score of this journal is 4.9, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Low impact journal.

Related Reading

• Belly Fat, Not Birthdays: What Actually Drives Low Testosterone in Men